Sapphire Star Partners LP Sells 800 Shares of Eli Lilly and Company (LLY)
Sapphire Star Partners LP reduced its stake in Eli Lilly and Company (NYSE:LLY) by 5.0% during the second quarter, Holdings Channel reports. The institutional investor owned 15,300 shares of the company’s stock after selling 800 shares during the period. Eli Lilly and comprises about 1.6% of Sapphire Star Partners LP’s holdings, making the stock its 18th largest position. Sapphire Star Partners LP’s holdings in Eli Lilly and were worth $1,259,000 at the end of the most recent quarter.
Other hedge funds have also bought and sold shares of the company. First Command Financial Services Inc. increased its stake in Eli Lilly and by 7.3% in the first quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock valued at $103,000 after buying an additional 84 shares in the last quarter. Heritage Trust Co purchased a new stake in Eli Lilly and during the first quarter valued at about $135,000. Point72 Asia Hong Kong Ltd increased its stake in Eli Lilly and by 237.4% in the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock valued at $148,000 after buying an additional 1,239 shares in the last quarter. Penserra Capital Management LLC increased its stake in Eli Lilly and by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock valued at $170,000 after buying an additional 176 shares in the last quarter. Finally, American National Bank increased its stake in Eli Lilly and by 5.2% in the second quarter. American National Bank now owns 2,088 shares of the company’s stock valued at $172,000 after buying an additional 104 shares in the last quarter. 75.61% of the stock is owned by institutional investors.
Shares of Eli Lilly and Company (NYSE:LLY) traded down 0.80% during midday trading on Thursday, hitting $81.91. 947,323 shares of the company were exchanged. Eli Lilly and Company has a one year low of $64.18 and a one year high of $86.72. The company has a 50-day moving average of $83.02 and a 200 day moving average of $81.68. The company has a market capitalization of $86.42 billion, a P/E ratio of 35.44 and a beta of 0.34.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating the Zacks’ consensus estimate of $1.05 by $0.06. The business had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. Eli Lilly and’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.86 earnings per share. On average, equities research analysts expect that Eli Lilly and Company will post $4.16 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.52%. The ex-dividend date is Friday, August 11th. Eli Lilly and’s dividend payout ratio (DPR) is presently 90.04%.
WARNING: This report was reported by Daily Political and is the property of of Daily Political. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.dailypolitical.com/2017/08/10/sapphire-star-partners-lp-sells-800-shares-of-eli-lilly-and-company-lly.html.
Several research firms recently issued reports on LLY. BidaskClub raised shares of Eli Lilly and from a “sell” rating to a “hold” rating in a report on Wednesday, June 14th. Barclays PLC upped their price objective on shares of Eli Lilly and from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Tuesday, July 4th. BMO Capital Markets reaffirmed a “sell” rating and set a $73.00 price objective on shares of Eli Lilly and in a report on Friday, August 4th. Berenberg Bank reaffirmed a “buy” rating and set a $100.00 price objective on shares of Eli Lilly and in a report on Thursday, July 27th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $96.00 target price (up from $93.00) on shares of Eli Lilly and in a research note on Thursday, July 13th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $88.27.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 220,000 shares of the business’s stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $83.09, for a total transaction of $18,279,800.00. Following the completion of the transaction, the insider now owns 124,049,283 shares of the company’s stock, valued at $10,307,254,924.47. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Melissa S. Barnes sold 1,900 shares of the business’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $80.78, for a total value of $153,482.00. Following the transaction, the insider now directly owns 14,041 shares of the company’s stock, valued at approximately $1,134,231.98. The disclosure for this sale can be found here. In the last ninety days, insiders sold 669,733 shares of company stock valued at $55,845,287. 0.20% of the stock is owned by insiders.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.